Medpace Holdings, Inc. — Q2 2020 Form 10-Q
Business context and reporting period. Medpace is a global clinical research organization providing drug and medical-device development services. This unaudited filing covers the quarter and six months ended June 30, 2020; comparisons are with the corresponding 2019 periods unless otherwise noted. The company had approximately 3,400 employees across 38 countries.
Financial performance
| Metric | Q2 2020 | Q2 2019 | Six months 2020 | Six months 2019 |
|---|---|---|---|---|
| Revenue | $205.0 million | $214.1 million | $435.9 million | $414.8 million |
| Operating income | $30.1 million | $35.3 million | $65.6 million | $61.2 million |
| Net income | $24.1 million | $27.5 million | $53.1 million | $46.7 million |
| Diluted EPS | $0.64 | $0.73 | $1.40 | $1.24 |
| Operating margin | 14.7% | 16.5% | 15.1% | 14.7% |
Operating margins are calculated from reported revenue and operating income. Q2 revenue fell 4.3% and net income fell 12.2%; for the first half, revenue rose 5.1% and net income rose 13.7%. First-half growth was driven mainly by Oncology and AVAI. Q2 weakness reflected COVID-19-related contraction in Cardiology, CNS, Metabolic and other areas. Higher personnel costs, including severance, partly offset lower reimbursed expenses in the quarter.
Cash flow and liquidity. First-half operating cash flow was $93.4 million, versus $80.6 million; investing cash outflow was $14.8 million, versus $7.3 million, primarily for property and equipment; financing cash outflow was $48.9 million, primarily from $50.8 million of share repurchases. Cash increased by $29.0 million to $160.9 million from $131.9 million at year-end 2019. Current assets were $319.1 million and current liabilities $338.0 million at June 30.
Debt and other balance-sheet items. Medpace reported no borrowings and $49.8 million available under its $50 million revolving credit facility, which expires March 31, 2021; $0.2 million of letters of credit were outstanding. Operating lease liabilities were $128.9 million, up from $56.2 million at year-end, including obligations associated with newly occupied headquarters space. Advanced billings were $195.4 million; accounts receivable and unbilled receivables, net, were $127.3 million.
Material changes, outlook and risks
- COVID-19: Management said the pandemic materially adversely affected both Q1 and Q2 and expects continued adverse effects, potentially material, but could not reasonably estimate the future financial impact. Site disruption, reduced trial starts, slower awards and patient recruitment, cancellations, client funding constraints, travel restrictions and closures are key risks. The company adopted virtual monitoring and other alternative approaches and made some staff reductions.
- Awards and backlog: Net new business awards were $254.1 million in Q2 and $501.0 million in the first half, compared with $279.2 million and $527.9 million, respectively, in 2019. Backlog was $1.343 billion at June 30, up 14.6% year over year; approximately $670–$690 million was expected to convert to revenue over the following 12 months. Management cautioned that awards and backlog may not reliably predict future revenue. No specific revenue or earnings guidance was provided.
- Capital returns: The company repurchased 772,125 shares for $50.8 million in the first half; $49.2 million remained under its $100 million authorization. Repurchases may be suspended or discontinued.
- Related parties and contingencies: The filing describes leases with entities owned by the CEO and family members, including the newly occupied headquarters building, as well as other related-party transactions. Management said ordinary-course legal proceedings and recorded reserves were immaterial; potential losses beyond recognized amounts were also believed immaterial. The company had $11.9 million of minimum purchase commitments through 2026.
- Other: The company reported no material changes to previously disclosed risk factors apart from the added COVID-19 discussion, no off-balance-sheet arrangements, and effective disclosure controls. Adoption of the expected-credit-loss accounting standard had no financial-statement impact.
Important facts for investors to verify
- How clinical-site disruption, recruitment delays, cancellations and client financing affect subsequent revenue, margins and cash collection.
- Whether backlog converts on expected timelines, and how awards, cancellations and the $670–$690 million near-term conversion estimate evolve.
- The outlook for personnel costs and severance, and whether Q2 operating-margin pressure persists.
- The economics, terms and governance of related-party leases, particularly the new headquarters lease and the increase in lease liabilities.
- The pace of share repurchases relative to operating cash generation and investment needs.